Streamlining processes like trial site selection and FDA documentation can make a meaningful difference in development ...

Integrating novel technologies in drug development and quality control, such as big data analytics, artificial intelligence, ...

The program taps into several OpenAI models and can be used across a wide range of therapeutic indications. Both Big Pharma ...

Drug Designing Tools Market. The global drug designing tools market is poised for significant expansion, anticipated to grow ...

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera ... s generative AI antibody design expertise, including its proprietary machine-learning-generated ...

As AI becomes more prevalent, organizations need to leverage the power of scope, scale, speed, and human-AI collaboration for ...

Nxera Pharma, previously known as Sosei Heptares or the Sosei Group, has entered a collaboration and licensing agreement with Antiverse to design antibodies for G-protein coupled receptors (GPCRs).

NTU Singapore is introducing two new undergraduate degree programmes in robotics and advanced chemical and pharmaceutical manufacturing in August 2025. The two programmes are designed to meet an ...

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – ...

Nxera Pharma & Antiverse collaborate to design novel GPCR-targeted antibody therapeutics using generative AI: Tokyo, Japan Wednesday, November 6, 2024, 13:00 Hrs [IST] Nxera Pharm ...